Progression-Free Survival Outcomes By Response Status for Bortezomib, Melphalan, and Prednisone with or without Daratumumab in Newly Diagnosed Multiple Myeloma: Pooled Subgroup Analysis of Octans and Alcyone

被引：1

作者：

Wang, Jianxiang ^{[1
]}

Fu, Weijun ^{[2
]}

Bang, Soo-Mee ^{[3
]}

Huang, Honghui ^{[4
]}

Kim, Kihyun ^{[5
]}

Li, Wei ^{[6
]}

An, Gang ^{[1
]}

Lee, Je-Jung ^{[7
]}

Cai, Zhen ^{[8
]}

Jin, Jie ^{[8
]}

Wang, Yafei ^{[9
]}

Chim, C. S. ^{[10
]}

Rodriguez-Otero, Paula ^{[11
]}

Liberati, Anna Marina ^{[12
]}

Takamatsu, Hiroyuki ^{[13
]}

Lee, Jae Hoon ^{[14
]}

Dimopoulos, Meletios A. ^{[15
]}

Wroblewski, Susan ^{[16
]}

Carson, Robin ^{[16
]}

Qi, Ming ^{[16
]}

Wang, Jianping ^{[17
]}

Song, Yang ^{[18
]}

Jia, Bin ^{[19
]}

Yang, Xue ^{[19
]}

Liu, Wenyu ^{[18
]}

Li, Yunan ^{[20
]}

Zhang, Renyi ^{[21
]}

Hou, Jian ^{[4
]}

机构：

[1] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol Blood Dis Hosp, Tianjin, Peoples R China

[2] Shanghai Changzheng Hosp, Shanghai, Peoples R China

[3] Seoul Natl Univ, Bundang Hosp, Seoul, South Korea

[4] Shanghai Jiao Tong Univ, Renji Hosp, Dept Hematol, Sch Med, Shanghai, Peoples R China

[5] Sungkyunkwan Univ, Dept Med, Samsung Med Ctr, Sch Med, Seoul, South Korea

[6] Jilin Univ, Dept Hematol, Ctr Oncol, Hosp 1, Changchun, Peoples R China

[7] Chonnam Natl Univ, Dept Hematol Oncol, Med Sch, Hwasun, Jeollanamdo, South Korea

[8] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China

[9] Tianjin Med Univ Canc Inst & Hosp, Dept Hematol, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc,Key Lab Canc Prevent &, Tianjin, Peoples R China

[10] Univ Hong Kong, Queen Mary Hosp, Hong Kong, Peoples R China

[11] Univ Navarra Clin, Pamplona, Spain

[12] Azienda Osped Santa Maria, Terni, Italy

[13] Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Dept Hematol, Fac Med, Kanazawa, Japan

[14] Gachon Univ, Gil Med Ctr, Incheon, South Korea

[15] Natl & Kapodistrian Univ Athens, Athens, Greece

[16] Janssen Res Dev LLC, Spring House, PA USA

[17] Janssen Res Dev LLC, Raritan, NJ USA

[18] Janssen Res Dev LLC, Beijing, Peoples R China

[19] Janssen Res Dev LLC, Shanghai, Peoples R China

[20] Xian Janssen Pharmaceut Ltd, Med Affairs, Beijing, Peoples R China

[21] Xian Janssen Pharmaceut Ltd, Med Affairs, Shanghai, Peoples R China

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-148937

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1648

引用

页数：5

共 50 条

[1] Daratumumab, Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in TransplantIneligible Patients with Newly Diagnosed Multiple Myeloma: Pooled Analysis of Octans and Alcyone
Hou, Jian
Fu, Weijun
Bang, Soo-Mee
Huang, Honghui
Kim, Kihyun
Li, Wei
An, Gang
Lee, Je-Jung
Cai, Zhen
Jin, Jie
Wang, Yafei
Chim, C. S.
Rodriguez-Otero, Paula
Dimopoulos, Meletios A.
Fujisaki, Tomoaki
Lee, Jae Hoon
Wroblewski, Susan
Carson, Robin
Qi, Ming
Wang, Jianping
Song, Yang
Bin Jia
Yang, Xue
Liu, Wenyu
Li, Yunan
Zhang, Renyi
Wang, Jianxiang
[J]. BLOOD, 2021, 138
[2] Subgroup Analyses of Progression-Free Survival from the Phase 3 Octans and Alcyone Studies in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Bortezomib, Melphalan, and Prednisone with or without Daratumumab
Fu, Weijun
Bang, Soo-Mee
Huang, Honghui
Kim, Kihyun
Li, Wei
An, Gang
Lee, Je-Jung
Cai, Zhen
Jin, Jie
Wang, Yafei
Chim, Chor Sang
Otero, Paula Rodriguez
Dimopoulos, Meletios A.
Fujisaki, Tomoaki
Lee, Jae Hoon
Wroblewski, Susan
Borgsten, Fredrik
Carson, Robin
Liu, Rui
Zhao, Man
Wu, Tingting
Chen, Xi
Cui, Canchan
Hou, Jian
Wang, Jianxiang
[J]. BLOOD, 2023, 142
[3] Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE
Mateos, Maria-Victoria
Dimopoulos, Meletios A.
Cavo, Michele
Suzuki, Kenshi
Knop, Stefan
Doyen, Chantal
Lucio, Paulo
Nagy, Zsolt
Pour, Ludek
Grosicki, Sebastian
Crepaldi, Andre
Liberati, Anna Marina
Campbell, Philip
Yoon, Sung-Soo
Iosava, Genadi
Fujisaki, Tomoaki
Garg, Mamta
Iida, Shinsuke
Blade, Joan
Ukropec, Jon
Pei, Huiling
Van Rampelbergh, Rian
Kudva, Anupa
Qi, Ming
San-Miguel, Jesus
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (11): : 785 - 798
[4] Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Overall Survival in Alcyone
Mateos, Maria-Victoria
Cavo, Michele
Blade, Joan
Dimopoulos, Meletios A.
Suzuki, Kenshi
Jakubowiak, Andrzej
Knop, Stefan
Doyen, Chantal
Lucio, Paulo
Nagy, Zsolt
Pour, Ludek
Cook, Mark
Grosicki, Sebastian
Crepaldi, Andre H.
Liberati, Anna Marina
Campbell, Philip
Shelekhova, Tatiana
Yoon, Sung-Soo
Iosava, Genadi
Fujisaki, Tomoaki
Garg, Mamta
Krevvata, Maria
Wang, Jianping
Kudva, Anupa
Ukropec, Jon
Wroblewski, Susan
Kobos, Rachel
San-Miguel, Jesus
[J]. BLOOD, 2019, 134
[5] Efficacy and safety of Daratumumab, Bortezomib, Melphalan, and Prednisone (D-VMP) versus Bortezomib, Melphalan, and Prednisone (VMP) in Chinese patients with newly diagnosed Multiple Myeloma: OCTANS
Fu, Weijun
Huang, Honghui
Li, Wei
An, Gang
Cai, Zhen
Jin, Jie
Wang, Yafei
Chim, Chor Sang
Qi, Ming
Wang, Jianping
Song, Yang
Jia, Bin
Yang, Xue
Liu, Wenyu
Li, Yunan
Zhang, Renyi
Hou, Jian
Wang, Jianxiang
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S125 - S125
[6] Bortezomib, Melphalan, and Prednisone With or Without Daratumumab in Transplant-ineligible Asian Patients With Newly Diagnosed Multiple Myeloma: The Phase 3 OCTANS Study
Fu, Weijun
Bang, Soo-Mee
Huang, Honghui
Kim, Kihyun
Li, Wei
An, Gang
Lee, Je-Jung
Cai, Zhen
Jin, Jie
Wang, Yafei
Lin, Tung-Liang
Chim, Chor Sang
Qi, Ming
Wang, Jianping
Lu, Xiaolin
Song, Yang
Jia, Bin
Yang, Xue
Liu, Wenyu
Zhou, Tianyuan
Yin, Lu
Li, Yunan
Zhang, Renyi
Hou, Jian
Wang, Jianxiang
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (06): : 446 - +
[7] Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial
Mateos, Maria-Victoria
Cavo, Michele
Blade, Joan
Dimopoulos, Meletios A.
Suzuki, Kenshi
Jakubowiak, Andrzej
Knop, Stefan
Doyen, Chantal
Lucio, Paulo
Nagy, Zsolt
Pour, Ludek
Cook, Mark
Grosicki, Sebastian
Crepaldi, Andre
Liberati, Anna Marina
Campbell, Philip
Shelekhova, Tatiana
Yoon, Sung-Soo
Iosava, Genadi
Fujisaki, Tomoaki
Garg, Mamta
Krevvata, Maria
Chen, Ying
Wang, Jianping
Kudva, Anupa
Ukropec, Jon
Wroblewski, Susan
Qi, Ming
Kobos, Rachel
San-Miguel, Jesus
[J]. LANCET, 2020, 395 (10218): : 132 - 141
[8] Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study
Fu, Weijun
Bang, Soo-Mee
Huang, Honghui
Kim, Kihyun
Li, Wei
An, Gang
Lee, Je-Jung
Cai, Zhen
Jin, Jie
Wang, Yafei
Chim, Chor Sang
Carson, Robin
Liu, Rui
Zhao, Man
Chen, Xi
Cui, Canchan
Hou, Jian
Wang, Jianxiang
[J]. ANNALS OF HEMATOLOGY, 2024,
[9] Cost-Effectiveness Analysis of Adding Daratumumab to a Regimen of Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma
Zeng, Xiaohui
Liu, Qiao
Peng, Liubao
Peng, Ye
Yi, Lidan
Luo, Xia
Li, Sini
Wan, Xiaomin
Tan, Chongqing
[J]. ADVANCES IN THERAPY, 2021, 38 (05) : 2379 - 2390
[10] Cost-Effectiveness Analysis of Adding Daratumumab to a Regimen of Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma
Xiaohui Zeng
Qiao Liu
Liubao Peng
Ye Peng
Lidan Yi
Xia Luo
Sini Li
Xiaomin Wan
Chongqing Tan
[J]. Advances in Therapy, 2021, 38 : 2379 - 2390

← 1 2 3 4 5 →